This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Click here for VYNDAQEL®▼ (tafamidis) Prescribing Information.
The referral guidance and templates below offer helpful information on how to refer a suspected or confirmed case of ATTR-CM to either the National Amyloidosis Centre (NAC) or Midlands Amyloidosis Service (MAS), depending on your region.
These materials are intended to support UK Healthcare Professionals.
National Amyloidosis Centre (NAC)
This referral guidance has been developed & funded by Pfizer and produced with input and permission from the NAC and offers information on how to refer a suspected or case of ATTR-CM to the NAC. This will enable the NAC to organise further diagnostic follow-up for suspected cases and initiate VYNDAQEL®▼ (tafamidis) for eligible adult patients with confirmed ATTR-CM.
This referral template has been developed & funded by Pfizer and produced with input and permission from the NAC and offers clinicians a downloadable template to complete with patient information if you have a suspected or confirmed case of ATTR-CM. the completed template to the NAC will enable further diagnostic follow-up for suspected cases and initiation of VYNDAQEL®▼ (tafamidis) for eligible adult patients with confirmed ATTR-CM.
This referral guidance has been developed & funded by Pfizer and produced with input and permission from the Midlands Amyloidosis Service (MAS) and offers helpful information on how to refer a suspected or confirmed case of ATTR-CM to the MAS. This will enable the MAS to organise further diagnostic follow-up for suspected cases and initiate VYNDAQEL®▼ (tafamidis) for eligible adult patients with confirmed ATTR-CM.
This referral template has been developed & funded by Pfizer and produced with input and permission from the Midlands Amyloidosis Service (MAS) and offers helpful information on how to refer a suspected or confirmed case of ATTR-CM to the MAS. This will enable the MAS to organise further diagnostic follow-up for suspected cases and initiate VYNDAQEL®▼ (tafamidis) for eligible adult patients with confirmed ATTR-CM.
Learn more about ATTR-CM and how VYNDAQEL works
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2026 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-13971. December 2025